GlassScriptPhysician profile
Christopher Miles Griffith
NPI 1588735617
$6,192.53
in general payments reported to CMS, 2019-2025
32 companies · $908 in 2025
The $908 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $197 · 2021: $147 · 2022: $1,860 · 2023: $906 · 2024: $1,112 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Education: $27.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.99 |
| Education | $27.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,442.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $783.14 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $480.00 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $464.47 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $228.05 | 2021-2023 | |
| Janssen Biotech, INC. | $192.01 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $179.93 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $159.16 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $146.60 | 2022-2023 | |
| Ardelyx, INC. | $115.96 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $113.83 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $112.78 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $107.93 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $87.76 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $85.83 | 2019-2024 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $65.56 | 2019-2024 | Injectafer |
| Ucb, INC. | $52.20 | 2019-2020 | |
| Gilead Sciences, INC. | $51.15 | 2019 | |
| Celltrion USA INC. | $46.46 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $40.88 | 2024 | Resmetirom |
| Evoke Pharma, INC. | $28.42 | 2023-2024 | Gimoti |
| Micro-Tech Endoscopy USA, INC. | $28.27 | 2024 | Lesionhunter |
| Redhill Biopharma INC. | $27.57 | 2021 | |
| Phathom Pharmaceuticals, INC. | $25.91 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $24.06 | 2025 | General - Therapies |
| Mallinckrodt Hospital Products INC. | $21.83 | 2025 | Terlivaz |
| Enterra Medical, INC. | $18.04 | 2023 | |
| Ambu INC. | $15.18 | 2022 | |
| Shire North American Group INC | $12.47 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.78 | 2022 | |
| Cook Medical LLC | $11.35 | 2020 | |
| Allergan, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.